Narrative review: The U.S. Pharmacopeia and Model Guidelines for medicare Part D formularies

Annals of Internal Medicine

Volumn 145, Issue 6, 2006, Pages 448-453

  Williams, Roger L ^a   Abernethy, Darrell R ^b   Bielory, Leonard ^c   Blum, Richard S ^d   Braden, Nancy J ^d   Calis, Karim A ^e   Campen, David H ^f   Finkelstein, Stan N ^g   Foster, Thomas S ^h   Horn, Mark L ⁱ   Kirking, Duane M ^j   Murray, Michael D ^k   Rucker, N Lee ^l   Schwartzberg, Joanne G ^m   Shepherd, Alexander M M ⁿ   Strnad, Colette F ^o   West, Dennis P ^p   Westrick, Edward ^q   Schuber, Stefan ^a  

^a UNITED STATES PHARMACOPEIA   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^d National Institutes of Health ^*  (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f KAISER PERMANENTE   (United States)

^g MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^h UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

ⁱ PFIZER INC   (United States)

^j UNIVERSITY OF MICHIGAN   (United States)

^k UNIVERSITY OF NORTH CAROLINA   (United States)

^l AARP   (United States)

^m AMERICAN MEDICAL ASSOCIATION   (United States)

ⁿ UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^o HEALTH CANADA   (Canada)

^p NORTHWESTERN UNIVERSITY   (United States)

^q University of Massachusetts   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETOHEXAMIDE; ANOREXIGENIC AGENT; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; ANTITUSSIVE AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; CHLORIDE; CHLORPROPAMIDE; FLUORIDE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; HERBACEOUS AGENT; IMMUNOSUPPRESSIVE AGENT; MALEIC ACID; METFORMIN; MIGLITOL; NATEGLINIDE; NEUROLEPTIC AGENT; NON PRESCRIPTION DRUG; PHOSPHODIESTERASE V INHIBITOR; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; TOLAZAMIDE; TOLBUTAMIDE; UNINDEXED DRUG; VITAMIN;

DRUG COST; DRUG FORMULARY; LAW ENFORCEMENT; MEDICAL EXPERT; MEDICAL LITERATURE; MEDICAL SOCIETY; MEDICARE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PUBLICATION; REVIEW; UNITED STATES; LEGAL ASPECT;

FORMULARIES; GUIDELINES; MEDICARE; PHARMACOPOEIAS; PRESCRIPTIONS, DRUG; UNITED STATES;

EID: 33749163672     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-145-6-200609190-00008     Document Type: Review

References (22)

1. Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Pub. L. No. 108-173 (2003).
2. Meyer BM, Cantwell KM. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003: implications for health-system pharmacy. Am J Health Syst Pharm. 2004;61:1042-51.
3. Doherty RB. Assessing the new medicare prescription drug law. Ann Intern Med. 2004;141:391-5.
4. Azar AM 2nd. What a Food and Drug lawyer should know about the Medicare Modernization Act. Food Drug Law J. 2004;59:217-22.
5. 42 U.S.C. 1395w-104(b)(3)(C)(ii).
6. Pub. L. No. 101-508, § 4401(a)(3) (1990).
7. Pub. L. No. 103-66, § 13553(b) (1993).
8. Principles of a sound drug formulary system. October 2000. Accessed at www.amcp.org/data/nav_content/drugformulary%2Epdf on 4 August 2006.
9. Booz Allen Hamilton. Formulary structure environmental scan for the United States Pharmacopeia. Accessed at www.usp.org/pdf/EN/mmg/approach Attachment1BAHScan2004-12-31.pdf on 4 August 2006.
10. 42 USC 1396r-8(d)(2), referenced in 42 USC 1395w-102(e)(2).
11. U.S. Pharmacopeia Medicare Model Guidelines: background and history. Accessed at www.usp.org/healthcareInfo/mmg/ on 4 August 2006.
12. United States Pharmacopeial Convention, Inc. Medicare prescription drug benefit: summary of USP approach and methodology to the model guidelines. 31 December 2004. Accessed at www.usp.org/pdf/EN/mmg/ finalApproachAndMethodology2004-12-31.pdf on 4 August 2006.
13. Department of Veterans Affairs, Pharmacy Benefits Management Strategic Healthcare Group. VA classes. Accessed at www.pbm.va.gov/PBM/menu.asp on 4 August 2006.
14. American Society of Health-System Pharmacists. McEvoy GK, ed. AHFS Classification: AHFS Drug Information 2004. Bethesda, MD: American Society of Health-System Pharmacists; 2004:ix-xii.
15. World Health Organization. 14th model list of essential medicines. Accessed at www.who.int/hac/techguidance/pht/essentialmed/en/ on 4 August 2006.
16. 42 U.S.C. 1395w-104(b)(3)(C)(i).
17. Centers for Medicare & Medicaid Services. Medicare Modernization Act final guidelines - formularies. Accessed at http://new.cms.hhs.gov/PrescriptionDrugCovContra/Downloads/FormularyGuidance. pdf on 4 August 2006.
18. Moon M. How Beneficiaries Fare under the New Medicare Drug Bill. New York: The Commonwealth Fund; 2004.
19. Centers for Medicare & Medicaid Services. Useful information on Medicare Advantage applications. 20 January 2006. Accessed at www.cms.hhs.gov/MedicareAdvantageApps/Downloads/Useful_Information.pdf on 3 August 2006.
20. Rucker TD. A public-policy strategy for drug formularies: preparation or procrastination? Am J Health Syst Pharm. 1999;56:2338-42.
21. Barkley GL. Epilepsy Foundation, Landover, Maryland. Letter to U.S. Pharmacopeia. 17 September 2004. Available at www.usp.org/healthcareInfo/ mmg/publicComments.html.
22. Olson SF. American Academy of Neurology, St. Paul, Minnesota. Letter to U.S. Pharmacopeia. 17 September 2004. Available at www.usp.org/healthcare Info/mmg/publicComments.html.